Sanofi symposium at NLC 2024
Biomarker-driven treatment of asthma – (when) is it worth it?
What is the value of biomarker-directed management of severe asthma in the current era of biologics? What is the recent evidence - is it really worth the trouble?
Welcome to this Sanofi symposium to hear the latest expert opinions on biomarker-directed treatment of asthma.
Program
Time: Friday 7.6.2024, 13:00-13:30
Place: Bysa 3, Clarion Hotel, Helsinki, Finland
Chair: Professor Lauri Lehtimäki, Tampere University & Tampere University Hospital
Biomarker-directed treatment as a way to improve asthma treatment
Professor Ian Pavord, Respiratory Medicine Unit & Oxford Respiratory NIHR BRC
Expert discussion: Biomarker-driven treatment of asthma – (when) is it worth it?
Professor Lauri Lehtimäki, Tampere University & Tampere University Hospital
Professor Ian Pavord, Respiratory Medicine Unit & Oxford Respiratory NIHR BRC
Professor Ian Pavord
Respiratory Medicine Unit & Oxford Respiratory NIHR BRC
Professor Lauri Lehtimäki
Tampere University & Tampere University Hospital
Recordings
The recordings will be published post the event.
Vill du läsa mer om behandling med Dupixent®(dupilumab) för de olika indikationerna, klicka in på Fass.se
Välj en behandling som riktar in sig på biologin bakom biomarkörerna*2-4
